Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has successfully completed enrollment and treatment of the last patient in its Phase I clinical trial of CUDC-101, Curis' first-in-class HDAC, EGFR and HER2 inhibitor.
“The completion of enrollment and the ensuing establishment of the maximum tolerated dose in this trial are important steps forward, both for the development of CUDC-101 and also for Curis' clinical development efforts as we continue to build a portfolio of partnered and proprietary targeted small molecules for cancer indications”
"The completion of enrollment and the ensuing establishment of the maximum tolerated dose in this trial are important steps forward, both for the development of CUDC-101 and also for Curis' clinical development efforts as we continue to build a portfolio of partnered and proprietary targeted small molecules for cancer indications," said Dan Passeri, Curis' President and Chief Executive Officer. "The ability to administer CUDC-101 at biologically active concentrations with what appears to be a favorable safety profile opens the way for the future clinical development of CUDC-101 and is an important step in validating Curis' proprietary platform of targeted small molecules capable of simultaneously inhibiting multiple nodes within a single cell."